FRANKFURT, Germany, Aug. 15,
2024 /PRNewswire/ -- Anbio, a leading provider of
innovative diagnostic solutions, made a significant impact at the
2024 Association for Diagnostics & Laboratory Medicine (ADLM)
conference, held in Chicago,
Illinois, from July 30 to August
1. This year, Anbio showcased its most comprehensive in
vitro diagnostics (IVD) solutions and an unmatched portfolio with
over 300 products applicable across various point-of-care testing
(POCT) scenarios, including CLIA (Chemiluminescence), FIA
(Fluorescence), RT-PCR, Lateral Flow Immunoassay, Dry Chemistry,
Hematology, and Veterinary test solutions.
Anbio simulated four real-world application scenarios at the
booth, including at-home, clinic, emergency room, and pharmacy
settings, allowing visitors to experience firsthand how Anbio's
various products can be applied in these situations. The company
also set up a Lab Demonstration Area where visitors could
experience the actual operation of each instrument. This real-time,
hands-on experience provided attendees with a better understanding
of the user-friendly and easy-to-use features of the products.
Anbio's robust immunoassay platform, featuring well-developed
CLIA and FIA solutions, has seen significant expansion in test
panels across multiple categories over the past year. The extensive
range of reagents in its menu caters to diverse clinical testing
needs, with over 80 FIA and more than 70 CLIA reagents available
for quality and quantity testing. These solutions are designed to
meet various clinical detection needs and enhance convenience for
healthcare providers. The newly developed dry chemiluminescence
solution, which requires less stringent conditions for
transportation and storage and offers higher stability, was a
highlight of the show, drawing substantial attention.
Anbio has always prioritized investment in R&D. At ADLM
2024, the company successfully launched its brand-new veterinary
diagnostic solution on both the Colloidal Gold and
immunofluorescent platforms. This launch has garnered significant
attention, highlighting the immense market potential for these new
offerings. With Anbio's unwavering commitment to product quality
and robust research and development capabilities, the Anbio
Veterinary Solution is poised to become a focal point in many
countries.
"ADLM 2024 provided a fantastic platform for us to
showcase our products and connect with clients from around the
world," said Michael Lau, CEO of
Anbio Biotechnology. "We thank everyone who visited our booth and
look forward to developing partnerships with other innovation
leaders in the IVD space."
About Anbio Biotechnology
Anbio Biotechnology is devoted to make contributions for human
health and has never stopped our goal to innovate in life sciences.
Driven by continuous technical development and integration,
resulting from close cooperation with prestigious institutes across
the world. Anbio always strives to provide total solutions in
clinical diagnosis field, by offering extensive diagnostic products
including laboratory and point-of-care products.
For more information, please visit: https://www.anbio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anbio-biotechnology-unveils-comprehensive-in-vitro-diagnostics-solutions-at-adlm-2024-302222709.html
SOURCE Anbio Biotechnology